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Since amyotrophic lateral sclerosis (ALS) was discovered and described in 1869 as a neurodegenerative disease in which motor
neuron death is induced, a wide range of biomarkers have been selected to identify therapeutic targets. ALS shares altered
molecular pathways with other neurodegenerative diseases, such as Alzheimer’s, Huntington’s, and Parkinson’s diseases. However,
the molecular targets that directly influence its aggressive nature remain unknown. What is the first link in the neurodegenerative
chain of ALS that makes this disease so peculiar? In this review, we will discuss the progression of the disease from the viewpoint
of the potential biomarkers described to date in human and animal model samples. Finally, we will consider potential therapeutic
strategies for ALS treatment and future, innovative perspectives.
1. Pathophysiology, Epidemiology,
and Essential Features of Amyotrophic
Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is an adult-onset, dev-
astating, neurodegenerative disease characterized by the loss
of cortical, brain stem, and spinal motor neurons. The
average survival from symptom onset is approximately 3 to
5 years, although some patients survive longer and exhibit a
slower disease progression. In accordance with the revised
El Escorial criteria [1], both the upper motor neurons and
the lower motor neurons degenerate or die in ALS, and,
as a consequence, the communication between the neuron
and muscle is lost, prompting progressive muscle weakening
and the appearance of fasciculations. In the later disease
stages, the patients become paralyzed and up to 50% of
ALS patients can show cognitive impairment, particularly
implicating more severe executive dysfunction and mild
memory decline [2–4].
ALS, which is one of the most common motor neuron
degenerative diseases, typically strikes adults during midlife.
Although ALS cases have been detected all over the world,
interestingly, the prevalence of the geographic loci of the
Western Pacific form of ALS is 50–100 times higher than
elsewhere in the world. The population of the Chamorro
people of Guam andMarianas is very well known. One of the
first studies performed in this population in 1957 described
a genetic origin of ALS associated with Parkinsonism and
dementia independent of environmental changes [5]. How-
ever, recent studies have noted a decreased incidence in these
areas over the past 40 years [6].
The majority of ALS cases are sporadic (SALS). Approx-
imately 5–10% of cases are the familial form of the dis-
ease (FALS), in which 20% have a SOD1 gene mutation
and approximately 2–5% have mutations in the TARDBP
gene (TAR DNA binding-protein, TDP-43) [7]. Addition-
ally, mutations in this gene also occur in SALS [6]. Other
genes, such as fusion in malignant liposarcoma/translocated
in liposarcoma (FUS/TLS), angiogenin (ANG), the vesicle-
associated membrane protein-associated protein B (VAPB),
senataxin (SETX), dynactin, and themost recently discovered
gene, a hexanucleotide repeat expansion in C9ORF72, have
been identified in ALS patients [8, 9]. These corresponding
gene mutations are responsible for ALS1 to ALS8, XALS,
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ALS/FTD1 and ALS/FTD2 disease forms [10, 11]. In partic-
ular, C9ORF72 gene has been defined as the most common
mutation in SALS and FALS, representing up to 6% and up to
40% respectively, with or without frontotemporal dementia
(FTD). This expansion shows a variable percentage of pene-
trance, which is directly correlated to the age of the patient.
From the molecular point of view, the mRNA transcript
of the C9ORF72 expansion diminishes the pool of RNA
binding proteins, deregulating finally the RNA metabolism
[12]. Other candidate genes that have been described in
ALS genome association studies, such as neurofilament,
peripherin [13], vascular endothelial growth factor (VEGF),
angiogenin, survival motor neuron (SMN), and hemochro-
matosis (HFE) [14], are also summarized in Table 1.
Most FALS cases have an autosomal dominant inheri-
tance pattern, although autosomal recessive patterns have
also been reported. For instance, the D90A mutation in
the SOD1 gene was detected in 3 of 28 German families
[15]; mutations in the ALS2 gene are linked to a locus
on chromosome 2q33, which has been described as a rare
juvenile form of ALS, andmutations in the ALS5 gene, linked
to chromosome 15q15.1-q21.1, are the most prevalent form of
autosomal recessive ALS, especially in families from Asia,
North Africa, and Germany [16]. Furthermore, the coexis-
tence of dominantly inherited FALS with other syndromes,
such as FTD and Parkinson’s disease, is also described. The
first case in which ALS coexisted with FTD was first reported
in 1975 [17] and was linked to a locus on chromosome 9q21-
q22, although the fact that different loci have also been linked
to this ALS-FTDphenotype suggests its genetic heterogeneity
[16]. Another ALS phenotype, FTD and Parkinson’s disease
(FTDP), was discovered in North America and was linked to
chromosome 17, showing clinical heterogeneity as in all cases
in whichmutations in themicrotubule-associated protein tau
gene (MAPT) located on chromosome 17q21 were described.
Moreover, genetic heterogeneity was also found whenMAPT
mutations were not common among all patients who had the
FTDP phenotype [16, 18].
The onset age of FALS, which follows a normal Gaussian
distribution, is a decade earlier than the onset age of SALS,
which has an age-dependent incidence. The incidence of
SALS is 1.89 people per 100,000/year and the prevalence is 5.2
people per 100,000.Themedian age of onset is approximately
60 years. The median survival ranges between 3 and 5 years
from symptom onset, which varies between 55 and 65 years
with a median age of 64 years [6, 16]. Onset before age 30,
called juvenile sporadic onset, is only found in 5% of cases.
The life-time risk of SALS by the age of 70 has been accurately
estimated to be 1 in 400 [6, 19].
Another important consideration is that many studies
have demonstrated that a slight excess of males are affected
with SALS compared to females, with a M : F ratio of approx-
imately 1.5 : 1, which may be due to protective hormones in
women. However, recent data suggest equality in this gender
ratio. Furthermore, bulbar onset is more common in women
and in older age groups and it is characterized by the presence
of dysarthria and dysphagia for solid and liquids and limb
symptoms that can develop almost simultaneously with the
bulbar symptoms, within 1 or 2 years in most cases. Paralysis
is a progressive process that leads to deathwithin 2-3 years for
bulbar onset cases and within 3–5 years for limb onset cases
[6].
A precise patient diagnosis is difficult, even for an experi-
enced clinician, because there are a wide range of motor neu-
ron diseases, such as FALS/SALS, spinal muscular atrophy
(SMA), hereditary spastic paraplegia (HSP), primary lateral
sclerosis (PLS), spinobulbar muscular atrophy (SBMA), or
Kennedy disease, that share common and heterogeneous
symptoms, such as weakness, spastic paralysis, or both,
reflecting a functional loss of upper and/or lower motor
neurons [20, 21]. ALS also includes dysfunction and loss of
both upper and lower motor neurons and spasticity may
gradually become present in the weakened limb, which can
affect manual dexterity and gait [6]. By definition, there
should be no autonomic, sensory, or cognitive involvement
[22]. Furthermore, the death of motor neurons tends to
occur in the distal segments toward the axial body region
and the clinical manifestation corresponds to the motor
neuron degeneration pattern. However, the evolution of the
degeneration is unique among ALS patients and the clinical
symptoms reflect these variations. Histopathological studies
have revealed cytoplasmic aggregate inclusions in the somata
and axons of surviving motor neurons, extensive gliosis, and
the presence of atrophic neurons or extensive neuronal loss
[21]. Moreover, ubiquitin, neurofilament subunits, and TDP-
43 are common proteins found within the inclusion bodies.
Particularly, TDP-43 was found in the neuronal inclusions
of both ALS and ALS-FTD patients and it may be used to
differentiate between SOD1 and non-SOD1 ALS cases [21].
2. Guidelines for Disease Diagnosis
ALS is a syndrome that appears to result from a complex
array of factors, including oxidative stress, mitochondrial
dysfunction, endoplasmic reticulum stress, dysregulated
transcription and RNA processing, dysregulated endosomal
trafficking, impaired axonal transport, protein aggregation,
excitotoxicity, apoptosis, inflammation, and genetic suscep-
tibility. All of these factors, or just some of them, can
contribute in different ways to the pathogenesis of the disease
(Figure 1). The potential role for glutamate excitotoxicity
in the pathophysiological process of FALS and SALS has
been thoroughly described during the past decade. An
excessive activation of the postsynaptic receptors N-methyl-
d-aspartate (NMDA) and 𝛼-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic (AMPA) and a significant reduction in
the expression of glutamate transporters (EAAT2, GLT-1),
which remove glutamate from the synaptic cleft, result in an
increased intracellular Ca2+ concentration, which prompts
glutamate excitotoxicity and, in later stages, motor neuron
death due to the production of free radicals [16, 23, 24]. From
an anatomical perspective, Eisen and colleagues proposed
that the dysfunction of upper motor neuron or corticomotor
neurons could induce deregulation in glutamate metabolism
and, as a result, an anterior horn cell degeneration in an
anterograde manner, which is known as the “dying forward
hypothesis.” This hypothesis has been supported by studies
demonstrating a cortical hyperexcitability in ALS patients,
BioMed Research International 3
Table 1: Gene mutations described in FALS and SALS, their chromosome location, Gene mutations described in FALS and SALS, their
chromosome location and their closely related molecular pathways.
Gene Chromosomelocation Deregulated pathway Clinical features
ANG
angiogenin 14q11.2 Angiogenesis pathway Sporadic ALS
APEX1
DNA repair enzyme
endonuclease
14q11.2-q12 Oxidative stress Sporadic ALS
C9orf72
Chromosome 9 open
reading frame 72
9p21.2 RNA metabolism Familial ALS found in sporadicALS, FTD
CHMP2B
chromatin modifying
protein 2B
3q11.2 Endosomal trafficking Familial ALS, FTD
CNTF
ciliary neurotrophic
factor
11q12.2 Neurotrophic factor, inflammation Sporadic ALS
DCTN1
dynactin 2q13
Deregulation of retrograde axonal
transport of vesicles and organelles Lower motor neuron disorder
FIG4
SAC domain-containing
protein
6q21 Trafficking endosomal vesicles Slow progression juvenile ALS
FUS/TLS
DNA/RNA-binding
protein
16q12.1-12.2 Transcriptional regulation, RNAsplicing and transport Familial and sporadic ALS
HFE
haemochromatosis 6q21.3 Disruption of iron metabolism Sporadic ALS
MAPT
microtubule-associated
protein tau
17q21 Neurofilament structure and axonalintegrity alterations
ALS disorder with Parkinsonism
and dementia
NEFL, NEFM, NEFH
neurofilaments chains 8q21; 22q12.1-q13.1
Neurofilament structure and axonal
integrity alterations Sporadic ALS
PGRN
progranulin 17q21.32
Induction of ubiquitin-positive
processes, TAU-negative FTD Sporadic ALS
PON
paraoxonase 7q21.2-q22.1
Failure in the detoxification of
organophosphate and neurotoxins Sporadic ALS
PRPH
peripherin 12q12-q13
Filament alterations in autonomic
nerves and peripheral sensory neurons Sporadic ALS
SETX
senataxin 9q34 DNA and RNA processing Slow progression juvenile ALS
SMN
survival motor neuron
gene
5q13.3 Child-onset spinal muscular atrophylinked to SMN1 mutations Lower motor neuron disorder
SOD-1
copper/zinc
superoxide-dismutase-1
21q22.1
Upregulation of protein
tyrosine-nitration
Improper metal ion binding
Upregulation of proinflammatory
cytokines
Formation of intracellular aggregates
Mitochondrial dysfunction
Reduced expression of glutamate
transporters
Deregulation of calcium homeostasis
Downregulation of intracortical
inhibitory processes
Cell death activation
Deregulation of Na+ and K+ cell
gradients
Slowing of anterograde transport
Familial ALS
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Table 1: Continued.
Gene Chromosomelocation Deregulated pathway Clinical features
SPG11
spatacsin 15q15.1-21.1 Axonal transport Slow progression juvenile ALS
TARDPB
tar DNA-binding protein 1q36.22
Neurodegeneration of neurons,
oligodendroglia, and astrocytes Familial and sporadic ALS
VAPB
vesicle-associated
membrane
protein-associated
protein B
20q13.33
Induction of the unfolded protein
response
altered transport and secretion
pathways
Familial ALS
VEGF
vascular endothelial cell
growth factor
6p12
Disease severity linked to SMN2
mutations
angiogenesis, permeability blood
vessels
Sporadic ALS
Dysfunction glial cells
Microglial cell
Oxidative stress mitochondrial
Apoptosis
Protein aggregation
Impaired glutamate transport
Motor neuron
Cytokine and immuno-
Axonal transport degeneration
Increase in Nogo A and  
Deficiency cholinergic synapses
Skeletal muscle
Astrocyte
 dysfunction (ROS)
immunoinflammatory factors production
extracellular matrix proteases expression
Figure 1: Schematic representation of the different molecular pathways altered in amyotrophic lateral sclerosis. Although the trigger for
neurodegeneration remains unknown, all of these deregulated mechanisms prompt motor neuron death.
which seemed to be an early feature in both FALS and SALS
[25, 26].
Despite the numerous studies that have attempted to
identify specific gene/protein targets exclusive to ALS and
characteristic of both FALS and SALS, the prognosis of the
disease remains poor. For this reason, the guidelines for ALS
diagnosis should be accurately defined.These guidelines were
first proposed by Lambert and colleagues [27], who consid-
ered that neurophysiologic symptoms, especially fascicula-
tions during electromyography (EMG), played an essential
role in ALS diagnosis and in the exclusion of other peripheral
neuromuscular pathologies. In particular, Lambert stated
that the presence of fasciculations on EMG recordings was
an essential feature for ALS diagnosis [27]. In 1990, the limits
of ALS were defined for the first time in the “El Escorial”
workshop for the purpose of facilitating clinical studies and
trials all over the world. The World Federation of Neurology
ResearchGroup onMotorNeuronDiseases developed the “El
Escorial” diagnostic criteria in 1994. Four years later, in the
revised “Airlie House” criteria, the diagnosis of patients was
divided into four categories: “clinically definite,” “clinically
probable,” “clinically probable-laboratory supported,” and
“clinically possible” [6, 28]. Indeed, these criteria appeared
to be more useful for research purposes and therapeutic
trials rather than clinical trials because some patients with
clinically obvious ALS failed to be categorized other than
clinically possible [28]. In fact, fasciculation potentials were
not accepted as evidence of active denervation, and their
absence raised diagnostic doubts [28]. A new criteria called
“Awaji-Shima” was proposed at an international symposium
in December 2006 during a consensus conference in Awaji-
shima, Japan, sponsored by the International Federation of
BioMed Research International 5
Clinical Neurophysiology [27]. The “Awaji-Shima” criteria
allowed EMG and clinical abnormalities to be combined
in the assignment of the diagnostic category of the patient
based on three categories: “clinically possible ALS,” “clinically
probable ALS,” and “clinically definite ALS”. In both criteria,
evidence of active and chronic denervation is required to
be confirmed by the presence of positive sharp waves and
fibrillation potentials and by the presence of long duration,
large amplitude, polyphasic, and unstable motor unit poten-
tials and decreased motor unit recruitment. In the “Awaji-
Shima” criteria, the presence of fasciculation potentials
denotes acute denervation, which is equivalent to fibrillation
potentials and positive waves according to the Lambert
criteria. These abnormalities must be present in at least two
muscles corresponding to the cervical and lumbosacral spinal
cord affected regions and in one muscle corresponding to
the brainstem and thoracic cord affected regions [27, 29].
Therefore, the accepted fasciculations should be complex
fasciculation potentials that occur in the presence of unstable
motor unit potentials in suspected ALS cases [27]. Carvalho
and Swash found a 95% increase in the sensitivity of the
diagnostic criteria for definiteALS, especially for bulbar onset
patients and for patients with “El Escorial” clinically possible
ALS, without loss of specificity compared to the “El Escorial”
criteria [29]. The use of the “Awaji-Shima” criteria reduces
periods of diagnostic uncertainty and repetitive testing and
enables earlier recruitment into clinical trials [30]. Another
useful instrument for the evaluation of the functional status
of ALS patients is the revised ALS Functional Rating Scale
(ALSFRS-r). This parameter can be used to monitor the
functional state of the patient over time and it includes the
measurement of speech, salivation, swallowing, handwriting,
cutting food and handling utensils, dressing and hygiene,
turning in bed and adjusting bed clothes, walking, climbing
stairs, and breathing.The progression of ALSFRS-r is strongly
related to survival and ALS prognosis [31].
3. Potential ALS Biomarkers Corresponding to
Disease Progression
According to the Biomarkers Definitions Working Group,
a biomarker, which has to be objectively measured and
evaluated, is “an indicator of normal biological processes,
pathogenic processes, or pharmacologic responses to a ther-
apeutic intervention” (DWG 2001) and “an indicator of func-
tional and structural changes in organs and cells.” Therefore,
biomarkers can also be considered potential therapeutic
molecular targets [32].
On the basis of their specific application to disease detec-
tion, biomarkers can be divided into three main categories
[32]: screening biomarkers, which may predict the potential
occurrence of a disease in asymptomatic patients; diagnos-
tic biomarkers, which are used to make predictions about
patients suspected of having the disease; and prognostic
biomarkers that are applied to predict the outcome of a
patient suffering from the disease. In the particular case of
ALS, during the last three decades, a wide range of potential
target molecules involved in different molecular pathways
have been described as possible biomarkers and these poten-
tial protein biomarkers could most likely fit in at least one of
the aforementioned categories. Which molecular biomarkers
are the key elements that induce neurodegeneration in ALS
in each stage of the disease?
Particularly useful for prognosis is the accurate identifi-
cation of the stage of the disease. Although the main causes
of the ALS disease remain unknown, the stage of the disease
can be estimated using the ALSFRS-r, as previously men-
tioned.The four main domains in the ALSFRS-r, swallowing,
walking/self-care, communicating, and breathing, have been
well characterized. Stages were defined as stage 0 (functional
involvement but no loss of independence on any domain),
stages 1–4 (number of domains in which independence was
lost), and stage 5 (death). However, recent studies devised
an algorithm to convert the ALSFRS-r score into clinical
stage, with an intraclass correlation coefficient of 0.92. This
algorithm provided a useful and reliable clinical stage using
the ALSFRS-r recorded [33]. Other ALS staging systems has
been also proposed.This is the case of the ALSMilano-Torino
Staging which combines the ALSFRS, quality of care (QOC),
and quality of life (QOL) measures. This system correlated
well with assessments of function, QOL, and health service
costs [34].More recently, another potential tool for predicting
disease progression is the multimodal magnetic resonance
imaging (MRI) of the spinal cord. This neuroimaging tool
has been mostly used in the study of neurodegenerative
changes in the brain, and therefore the focus of these studies
on ALS was mainly the upper motor neuron involvement.
Notwithstanding, spinal cord MRI, apart from its technical
limitations, gives the opportunity to extend the study to the
lower motor neuron area. In particular, spinal cord cross-
sectional area and the magnetization transfer ratio (MTR)
were found reliable and sensitive markers of the disease
progression in 29 patients with probable or definite ALS.The
atrophy rate of change obtained by these markers strongly
correlated with the rates of change in the arm ALSFRS-r and
manual muscle testing (MMT) subscores [35].
In the literature and from the molecular point of view
a range of potential biomarkers of disease progression have
been defined. In the asymptomatic stage, no visible signs can
be detected. In the symptomatic stage, the first clinical symp-
toms and functional deficits start to appear. The advanced or
terminal stage corresponds to the end-stage of the disease.
Although a wide range of molecular targets and potential
biomarkers have been studied and their relationship to a
specific disease stage has also been shown, few molecular
targets have been defined as potential ALS biomarkers based
on their relevant role in the prognosis and diagnosis of the
disease (Figure 2).
The asymptomatic stage or early asymptomatic stage
is the most critical stage and an accurate identification of
potential biomarkers in the asymptomatic stage could enable
early disease prognosis. More than 18 murine ALS models
have contributed not only to a better understanding of
the disease but also to the search of potential therapeutic
strategies. Nogo, also known as Neurite outgrowth inhibitor
or Reticulon-4, was one of the first potential biomarkers
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Figure 2: Time course of disease progression and identification
of related potential biomarkers involved in each stage. Reliable
biomarkers can be helpful in the prediction of different disease
stages and will facilitate the application of accurate therapeutic
treatments.
suggested in early asymptomatic transgenic SOD1G86R mice
[36, 37]. Nogo is a member of the myelin-associated proteins,
which possess axonal growth inhibitory activity. Three iso-
forms of this Neurite outgrowth inhibitor have been identi-
fied, Nogo A, Nogo B, and Nogo C. In particular, blocking
Nogo A during neuronal damage has been proposed as a
potential therapeutic strategy for autoimmune diseases, such
as multiple sclerosis [38]. Interestingly, Nogo could also have
a central role inALS.Nogo is upregulated in the lumbar spinal
cord of asymptomatic transgenic SOD1G86R mice and has
three isoformswhose expression levels peak at different stages
before the onset of pathological symptoms [36]. Furthermore,
in the skeletal muscle from these transgenic mice, Nogo A
expression levels increased close to the onset of the disease
and Nogo C expression levels decreased before the first
pathological signs in parallel with the overexpression of
AChR𝛼, which is amarker of denervation [36].These findings
suggested for the first time that the differential patterns of
Nogo A and Nogo C could be relevant to the asymptomatic
stage of the disease and the same profile pattern was observed
in postmortem muscle samples and in muscle biopsies
from ALS patients [36]. Another relevant result of these
findings was that Nogo A and Nogo B protein levels were
systematically increased exclusively in ALS patients and they
correlated with the severity of motor impairment assessed
by the ALS functional rating scale (ALSFRS) [39], which
opened the door to the study of this potential biomarker
in unexplored tissues. In accordance with muscle weakness,
reduced levels of Vgf nerve growth factor inducible peptide,
a member of the chromogranin/secretogranin family of
proteins, in the cerebrospinal fluid (CSF) were proposed as
a useful indicator of disease progression [40].The hypothesis
suggested by Zhao and coworkers was based on the reduced
levels of Vgf found in CSF, serum, and spinal cord motor
neurons from ALS patients, resembling the same findings in
the asymptomatic transgenic SOD1G93A mice. Consequently,
the downregulation ofVgf levels in spinal cordmotor neurons
could promote neurodegeneration, prompting NMDA and
AMPAexcitotoxicity injury [40]. Similarly, upregulated levels
of glial fibrillary acidic protein (GFAP) were also found in the
spinal cords of 25–30-day-old transgenic SOD1G93A mice and
this upregulation was associated with the onset of paralysis at
the symptomatic stage [41].
Regarding the symptomatic stage, a wide range of
ALS biomarkers have been proposed in different tissues.
Numerous studies have demonstrated the potential nature
of relevant biomarkers in the spinal cord, which is one
of the most affected tissues. Monitoring the levels of 5-
methyltetrahydrofolate (5-MTHF), folic acid, and homocys-
teine (Hcy) could provide useful information about the early
signs of the disease. Decreased levels of 5-MTHF were found
in the plasma, spinal cord, and cortex during the early
presymptomatic transgenicmice SOD1G93A prior to folic acid
reduction. Interestingly, the deficiency observed in 5-MTHF
and folic acid was followed by an increase in Hcy levels after
motor symptoms appeared in this animal model, suggesting
that 5-MTHF could be a potential biomarker in the early
disease stages [42]. With a clear connection to the spinal
cord and brain, microglial cells are also extremely sensitive
to pathological changes in the CNS. In fact, a dysregulation
of these cells can give rise to neurological diseases. Interest-
ingly, enhanced expression of the growth factor progranulin
(PGRN) in microglia from transgenic SOD1 mice during
disease progression was observed in the spinal cord and
CSF. Consequently, the upregulation of PGRN, which begins
during the symptomatic stage, could serve as a marker of
microglial response corresponding to disease progression
[43]. In agreement with this study, there is growing evidence
for the role of glial cells in the initiation of the disease. A
deficit in the number of microglial cells was reported in the
spinal cord from transgenic SOD1G93A mice at 30 days of age,
reflecting an intrinsic alteration of this cell population that is
tightly connected to an immune deficit even before the early
symptomatic stage [44]. However, activated microglial cells
could produce nitric oxide (NO) during symptomatic and
late stages, contributing to the neurodegenerative processes
of the disease. A significant upregulation of isoenzyme
inducible NO synthase (iNOS) was observed in spinal cord
glial cells from transgenic SOD1G93A mice during the early
symptomatic and end-stages, prompting the formation ofNO
and other reactive species, favoring an oxidative stress state
inmotor neurons. Contrary to iNOS regulation, the neuronal
NO synthase isoform (nNOS), another source of NO, showed
a downregulation in the spinal cord of SOD1G93A mice over
the course of ALS. This downregulation in nNOS enzymatic
activity was observed in parallel to the reduced number of
motor neurons, suggesting that nNOS activity could also be a
usefulmarker of spinal cord neurodegeneration in thismouse
model [45].
Recent studies have shown that 𝑇
2
-weighted magnetic
resonance imaging (MRI) was sensitive to pathologic changes
in brainstem nuclei from transgenic SOD1G93A mice at symp-
tom onset. Therefore, 𝑇
2
-weighted MRI has been proposed
as a leading candidate biomarker of disease progression in
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this animal model. Furthermore, the results obtained by this
noninvasive assessment correlated with histologic measures
of vacuolation and GFAP and Iba1 staining, which were
significantly greater during the symptomatic to late stage of
the disease [46].
Particularly interesting is the alteration of the blood brain
barrier (BBB) and blood spinal cord barrier (BSCB) during
disease progression. The BBB/BSCB impairment could serve
as a hallmark preceding clinical symptoms. In SOD1G93A
rats, decreased mRNA levels of the tight junction proteins
zonula occludens (ZO-1), occludin, and agrin were observed
during the symptomatic stage, pointing to an alteration in the
BBB/BSCB permeability and development. The BBB/BSCB
integrity was also found to be altered, possibly due to the
mutant SOD1 toxicity on endothelial cells and other factors
released as a direct consequence of the induced inflam-
mation during the last stage of the disease [47]. However,
for SOD1G93A mice, neither BBB leakage nor upregulation
of VCAM-1 expression has been proposed as a substantial
aspect of pathology [46]. The presence of different molecules
in the blood has a clear connection with BBB and BSCB
integrity and these molecules come from other damaged
tissues during disease progression. One example is matrix
metalloproteinase-9 (MMP-9) levels in the serum. Serum
MMP-9 activity was significantly elevated in presymptomatic
transgenic SOD1G93A mice, preceding a later decrease of its
activity in later disease stages. The upregulation of MMP-9
during early disease stages could indicate a response to spinal
cord pathology and other damaged tissues, such as skeletal
muscles and peripheral nerves. Therefore, circulating MMP-
9 activity in the blood could reflect disease progression in this
animal model [48]. However, previous studies on the CSF
of ALS patients did not reveal a significant upregulation of
MMP-9 levels [49].
Other useful diagnostic ALS biomarkers have been
described in more accessible tissues, such as blood or urine
samples. Closely related to the inflammatory response, 11,
15-dioxo-9-hydroxy-,2,3,4,5-tetranorprostan-1,20-dioic acid
(tPGDM), a metabolite of prostaglandin D2, could also
play an important role in the presymptomatic stages
and evaluation of ALS. Prostaglandins could mediate
neurodegeneration in ALS and muscle dystrophy. A sig-
nificant correlation between urinary tPGDM concent-
ration and ALS progression could provide a presymptomatic
diagnosis of the disease. Furthermore, the accuracy of this
analysis was improved when the combination of urinary
tPGDM and creatinine levels was monitored during disease
progression [50]. Another attractive candidate that can
be measured in an accessible tissue, such as blood, is the
heavily phosphorylated axonal form of neurofilament H
(pNF-H). pNF-H levels were upregulated in the blood from
rodent ALS models and ALS patients. Interestingly, this
upregulation correlated with a decline in ALSFRS-R score
in ALS patients, supporting the possibility of using this
molecule as a biomarker for disease prognosis [51].
Survival has been used as a relevant factor, mainly in
transgenic animal models where disease progression is rapid.
In skeletal muscle biopsies from transgenic SOD1G93A mice,
five genes (myocyte enhancer factor 2C (Mef2c), glutathione
reductase (Gsr), collagen, type XIX, alpha 1 (Col19a1),
calmodulin 1 (Calm1), and sorting nexin 10 (Snx10)) have
been proposed as potential genetic biomarkers of longevity
because their expression levels in skeletal muscle during
disease progression could be used to predict the longevity
of the animals. In light of this, In light of this, animals
that displayed downregulated leves of these genes during the
early symptomatic stage, showed a longer survival rate than
animals that presented an upregulation in these levels.There-
fore, these animals possibly exhibited a higher regenerative
capacity of skeletal muscle [52].
In the advanced disease stage, identifying which target
molecule is involved in the causative pathways of the disease
andwhich is a bystander phenomenon is very difficult. At this
step, the identification of ALS-specific protein biomarkers
in the CSF or serum could provide invaluable information
about the nature of the degenerativeALS process becauseCSF
or blood can be a source of proteins and protein fragments
released from affected neuronal and nonneuronal cells. An
example of protein biomarkers with diagnostic predictive
value comes from a study based on mass spectrometry
(surface enhanced laser desorption/ionization time-of-flight
mass spectrometry, SELDI-TOF-MS) of transthyretin, cys-
tatin C, and carboxy-terminal fragment of neuroendocrine
protein 7B2 (7B2CT) in the CSF samples of late-stage and
postmortem ALS patients. Decreased levels of transthyretin
could suggest a failure in the transport of thyroxine and
retinol/vitamin A. Consequently, this decrease would result
in an inadequate sequestration of abnormally functioning
proteins. Similarly, a reduction of cystatin C levels in CSF
samples could indicate increased proteolysis via cysteine
proteases. However, increased levels of 7B2CT could repre-
sent a reactive response to altered enzymatic activities that
generate or degrade 7B2CT, or it could result from Golgi
fragmentation within motor neurons during ALS [53].
Another potential ALS biomarker of tissue degeneration
was studied in the blood and CSF of ALS patients. The
activity of transglutaminase, a calcium-dependent enzyme
that accelerates the cross-linkage of polypeptide chains by
catalyzing the covalent binding of polyamines to g-glutamine
residues of protein molecules, was monitored in the serum
and CSF of SALS patients. There was a positive correlation
between the serum enzyme activity and ALS scores. In the
CSF, the enzyme activity was significantly downregulated
in SALS patients after the middle disease stage with ALS
clinical scores more than 250, suggesting that transglutami-
nase activity could be used as a general marker of neuronal
degeneration during disease prognosis [54].
Exploring minimally or noninvasive samples, such as
salivary samples, is also particularly interesting for the late
disease stage. Chromogranin A (CgA), an endocrinological
stress marker, is a soluble protein that can be measured
in saliva. Salivary CgA levels have a significant positive
correlationwith emotional function scores on the ALSAQ-40
in middle stage ALS patients and these levels were also found
upregulated in terminal ALS patients. Consequently, salivary
CgA could be used as a useful quantitative biochemical
marker of the affective state from symptomatic to terminal
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disease stages and therefore salivary CgA levels could make
more effective, tailor-made psychophysiological therapies for
individual ALS patients [55].
Finally, a new type of ALS biomarker is emerging from
epigenetics. The connection between methylomics and tran-
scriptomics data could reveal methylation changes in ALS
tissues, such as the spinal cord or blood. Blood samples
are particularly interesting because blood is a minimally
invasive alternative sample source for ALS prognostic and
diagnostic assessments. In particular, a recent study showed
alterations in global methylation and hydroxymethylation in
postmortem spinal cord samples of SALS patients. Precisey,
more than a hundred genes associated with biological func-
tions related to immune and inflammation responses were
identified as differentially methylated in this study, high-
lighting the role of inflammatory changes in the advanced
stage of the disease [56]. Epigenetics is a new field exploring
potential ALS biomarkers and further studies are needed
to integrate the new findings into our current knowledge.
Genome-wide association studies can undoubtedly provide
a better understanding of ALS.
4. An Update on the Therapeutic
Strategies for ALS
Inflammation, apoptosis, and oxidative stress are the selected
neurodegenerative pathways in ALS that are commonly
tackled by therapeutic treatments.
To prevent neuronal loss and motor dysfunction and
to increase survival time, potent antioxidants, such as iron
chelating compounds, 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-
trifluoromethyl-benzylamino)-benzoic acid (Neu2000), ce-
lastrol, an antioxidant peptide (SS-31) or lipophilic metal
chelators DP-109 and DP-460 and inhibitors of proapoptotic
proteins, such as lithium carbonate (Li+), have been tested
in transgenic SOD1G93A mice, yielding positive results
[57–61]. Similarly, in wobbler mice, another murine ALS
model, treatment from 4 to 9 weeks of age with rhTNF-𝛼
binding protein (rhTBP-1) reduced the progression of symp-
toms, motor neuron loss, gliosis, and JNK/p38MAPK phos-
phorylation, which are two main effectors in the neuro-
inflammatory response [62]. Immunomodulatory agents,
such as themonoclonal antibody to CD40L, amembrane gly-
coprotein that is primarily expressed on activatedT cells, have
also paved the way to the identification of cellular pathways
directly involved in potential therapeutic interventions. In
fact, treatment with anti-CD40L antibody reduced markers
of neuroinflammation, increased the number of motor
neuron cell bodies, decreased peripheral nervous system
(PNS) inflammatory markers, and downregulated expres-
sion of costimulatory genes in the spinal cord of transgenic
SOD1G93A mice [63]. Furthermore, the use of thalidomide
and its analogue lenalidomide inhibits the expression of
TNF-𝛼 and other cytokines, showing neuroprotective pro-
perties and significantly increasing the life span of SOD1G93A
transgenic mice [64].
Previous studies have suggested the potential role of
neurotrophic factors on motor neuron differentiation in
vitro [65]. Combined treatment with these neuroprotective
proteins can open the door to a new tool for the treatment
of motor neuron diseases such as ALS. Although ciliary neu-
rotrophic factor (CNTF), glial-derived neurotrophic factor
(GDNF), insulin-like growth factor (IGF-1), and erythropoi-
etin (EPO) improved motor behavior and reduced motor
neuron loss and astrocyte/microglia activation in preclinical
animal models [66, 67], clinical trials in ALS patients lacked
therapeutic efficacy [68]. However, melatonin treatment has
demonstrated preclinical and clinical effectiveness and high-
dose melatonin could be suitable for clinical trials aimed at
neuroprotection through antioxidation in ALS [69]. More
recently, although the inhibition of epidermal growth fac-
tor receptor (EGFR) signaling with erlotinib might protect
neurons from degeneration, no extended survival has been
observed in transgenic SOD1G93A mice. Consequently, the
expected effect of this EGFR inhibitor in vivo lacked efficacy
in this animal model [70]. Another novel molecular target
that could provide a promising strategy for ALS is S1R,
an endoplasmic reticulum- (ER-) resident receptor with
chaperone-like activity. S1R can participate as a modulator
in Ca2+ homeostasis, ER stress reaction, and apoptosis.
Interestingly, mutations of the S1R gene are associated with a
familial form of FTLD, which was at the same time associated
with MND and a familial juvenile form of ALS. Treatment
with an S1R agonist, PRE-084, improved locomotor function
and motor neuron survival in presymptomatic and early-
symptomatic mutant SOD1G93A mice, resembling the neuro-
protective effects previously tested in vitro [71].
Other therapeutic agents that have been mainly tested
in murine ALS models are antiglutamatergic agents, such as
Riluzole; the calcium regulators Verapamil and Nimodipine;
creatine, a mitochondrial enhancer and antiviral therapeu-
tic molecules such as interferon-𝛼 [67]. A wide range of
agents associated with protein repairing pathways and chap-
erone activation (Arimoclomol), sodium channel blockers
(Mexiletine), and others are undergoing clinical trials as
shown on the main web page of the “ALS Association”
(http://www.alsconsortium.org/trials.php). More in depth,
Riluzol is the only drug licensed for symptomatic ALS
treatment. The neuroprotective properties of Riluzol have
been well documented in vitro in a rat ALS model, providing
evidence of its neuroprotective action on motor neurons and
glia after the induction of an excitotoxic stimulus [72]. Riluzol
was approved for use in 1996, although 18 years later and
many trials later no efficient treatment has been found to
halt the neurodegenerative progression of the disease. Two
randomized controlled trials showed that Riluzol reduced
mortality modestly with few common side effects. Riluzol
extended survival by about 11%. Since these two trials, more
than 30 trials have reached negative results. Only other
positive trial tested efficacy of a medication based on the
combination of dextromethorphan and quinidine (AVP-
923; Nuedexta). This treatment alleviated the symptoms
of pseudobulbar affect in a multicenter, randomized, and
controlled trial [73]. Finally, another antiglutamatergic agent
that could open a new door to future therapeutic strategies
in ALS patients is Gacyclidine (GK11), a noncompetitive
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N-methyl-D-aspartate (NMDA) receptor, which has already
been used in two clinical trials for CNS lesions. Chronic
treatment with a low dose of GK11 in transgenic SOD1G93A
mice during the early symptomatic stage improved survival
and delayed locomotor function impairment [74].
5. Innovative Perspectives and
Concluding Remarks
Gene and stem cell therapies are holding hope for an efficient
ALS treatment. Regarding gene therapy, the possibility of
delivering therapeutic molecules (IGF, VEGF, GDNF, BDNF,
Bcl2) to damaged tissues crossing the blood-brain barrier
has been made possible by the study of viral (adenovirus,
adenoassociated and lentivirus) and nonviral (fragment C
of tetanus toxin) vectors. These vectors are retrogradely
transported to motor neurons in preclinical animal models
and demonstrate promising neuroprotective effects [75–78].
Moreover, the use of small interfering RNAs (RNAi) is an
alternative gene therapy approach based on the knockdown
of genes that might be causing neurodegeneration, such as
mutant SOD1 or Fas receptor [78, 79]. More recently and in
connection with C9ORF72 expansion, a strategy based on
antisense oligonucleotides directed to C9ORF72 transcript
or repeat expansion induced amelioration in the C9ORF72
pathogenic gain of function and in the vulnerability to
excitotoxicity in vitro [12]. More information about rele-
vant projects that are selected from a multidisciplinary
perspective can be found on the main web page of “The
Robert Packard Center for ALS Research at Johns Hopkins”
(http://www.alscenter.org/als science/research projects/). For
example, one project is currently studying the effectiveness
of adenoassociated virus (AAV9) delivery to carry IGF-1 and
VEGF to astrocytes.
Similar promising treatments are being carried out with
stemcell therapies, which is the newest therapeutic treatment.
To date, stem cell research remains at a preclinical level
and the most used treatments in ALS animal models are
based on neural or precursor stem cells [80] that can also
be modified to release neurotrophic factors, such as GDNF
[81]. Cell therapy studies based on mesenchymal stem cell
(MSC) transplantation noted the potential benefit of neural
induction by neurogenin 1 from transplanted MSCs in the
delay of disease onset and in the enhancement of motor
functions in transgenic SOD1G93A mice [82]. More recently,
ongoing clinical trials based on fetal-derived neural stem
cell injection in ALS patients try to assess the safety and
feasibility of this potential therapeutic approach into lumbar
and/or cervical spinal cord regions. The preliminary results
have suggested that this cell therapy is well-tolerated and
pave the way for future trial phases in order to determine the
therapeutic dose and efficacy [83, 84].
Although the development of therapeutic strategies that
could stop or reverse ALS progression is one of our main
research goals, the lack of fully validated and clinically
implemented biomarkers is a challenging barrier.The hetero-
geneity of ALS is characterized by the involvement of many
altered pathways and therefore the unknown cause of the
neurodegenerative process makes the task of finding definite
and specific disease biomarkers difficult. However, despite
the multifactorial etiology of ALS, all of the affected proteins
and genes that participate and contribute to the lethality of
the disease should not be studied independently but as a
whole. As in Ockham’s Razor, “do not multiply entities beyond
necessity,” when several explanations of increasing complex-
ity are found dealing with ALS, the simplest explanation
usually appears to be the most probable. At this point, the
most accurate knowledge of FALS addresses SOD1mutations
and the only potential biomarkers are described for SALS.
However, the new discovery of biomarkers will facilitate a
better understanding of this neurodegenerative disease and
will facilitate translation from animal models to patients for
a definitive therapeutic approach.
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